Medical Devices cover a wide range of products—from wound care plasters to surgical robots—and are deeply embedded in healthcare and daily life. The industry is equally diverse, involving large multinationals, SMEs, contract manufacturers, and R&D service providers. Unlike more consolidated sectors such as software or automotive, MedTech remains highly fragmented, mainly due to the variety of products. While large companies tend to be more risk-averse in breakthrough innovation, they excel at setting treatment standards and rapidly scaling new products globally. Market dynamics vary widely, from tender-driven hospital sales to reimbursed outpatient and OTC markets. Global supply chains and increasing outsourcing help companies control costs, although geopolitical risks, trade conflicts, and tariffs pose significant threats to this structure. Firms following a “local for local” production strategy are typically better positioned to absorb such shocks. With strong financial and operational resources, large MedTech companies are better equipped to handle complex regulatory frameworks, from device approvals to sustainability and post-market surveillance. Their installed product base also offers a strategic advantage for future innovations, especially in areas like AI, where linking diagnosis and treatment will rely on large data sets. Despite ongoing global uncertainty, demographic trends, expanded insurance coverage, and steady innovation suggest robust growth prospects for both commodity suppliers and high-tech leaders.